Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Trial details
- Registry ID
- NCT07570654
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT07570654 | COMPASS Pathways | Phase 2, Phase 3 | Recruiting | 2028-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |